RxDoctor Payments Data

Tracy Ridgill, MD

Family Medicine · Sumter, SCNPI 1558674812

Payments from drug & device makers

$8,493in general payments, 2019–2025

Across 412 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$968
  • Novo Nordisk$920
  • Lilly USA, LLC$610
  • Abbott$561
  • AstraZeneca$476
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$8,39799%
  • Education$50%
  • Gifts$911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,493 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$166,159
Medicare patients
325
Services billed
4,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide91$130,386
OzempicSemaglutide82$108,051
JardianceEmpagliflozin102$101,753
TrulicityDulaglutide74$101,243
EliquisApixaban78$66,385
JanuviaSitagliptin Phosphate48$59,507
FarxigaDapagliflozin Propanediol56$55,999
LinzessLinaclotide84$54,924
XareltoRivaroxaban22$32,158
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,490
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$20,524
Repatha SureclickEvolocumab26$20,463
Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag11$17,693
RybelsusSemaglutide12$17,266
Tresiba Flextouch U-100Insulin Degludec22$15,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$610$231,630165 claims
Novo NordiskOzempic, Rybelsus$920$125,31694 claims
Boehringer IngelheimJardiance$138$101,753102 claims
AstraZenecaFarxiga, Breztri Aerosphere$476$76,52372 claims
PfizerEliquis$393$66,38578 claims
MerckJanuvia, Janumet$91$66,27060 claims
AbbVieLinzess$1,043$54,92484 claims
Johnson & JohnsonXarelto$239$32,15822 claims
GSKTrelegy Ellipta$114$21,49025 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$287$10,41015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →